These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11933550)

  • 1. [CAPRICORN and COPERINUS studies].
    Juillière Y
    Arch Mal Coeur Vaiss; 2002 Feb; 95 Spec 4(5 Spec 4):17-20. PubMed ID: 11933550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and methodology of the CAPRICORN trial - a randomised double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction.
    Dargie HJ
    Eur J Heart Fail; 2000 Sep; 2(3):325-32. PubMed ID: 10938495
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
    Dargie HJ
    Lancet; 2001 May; 357(9266):1385-90. PubMed ID: 11356434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New evidence from the CAPRICORN Trial: the role of carvedilol in high-risk, post-myocardial infarction patients.
    Sackner-Bernstein JD
    Rev Cardiovasc Med; 2003; 4 Suppl 3():S25-9. PubMed ID: 14564231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Landmark study: the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study (CAPRICORN).
    Colucci WS
    Am J Cardiol; 2004 May; 93(9A):13B-6B. PubMed ID: 15144931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Congestive heart failure and acute myocardial infarction: latest trials with beta-blocking agents].
    Isnard R
    Ann Cardiol Angeiol (Paris); 2002 Jan; 51(1):48-50. PubMed ID: 12510669
    [No Abstract]   [Full Text] [Related]  

  • 7. Carvedilol: use in chronic heart failure.
    Doughty RN; White HD
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):21-31. PubMed ID: 17187454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effectiveness of carvedilol in heart failure].
    Kárpáti K; Brodszky V; Farsang C; Jermendy G; Vándorfi G; Zámolyi K; Gulácsi L
    Orv Hetil; 2006 Oct; 147(40):1931-7. PubMed ID: 17111685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on pharmacological advances.
    Fonarow G
    J Invasive Cardiol; 2004 Sep; 16 Suppl E():2E-6E. PubMed ID: 23573649
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial].
    Costalunga A; Gavazzi A
    Ital Heart J Suppl; 2001 Nov; 2(11):1246-7. PubMed ID: 11775420
    [No Abstract]   [Full Text] [Related]  

  • 11. Slowing the progression of heart failure.
    Cohn JN
    Eur Heart J; 1996 Nov; 17(11):1609-11. PubMed ID: 8922902
    [No Abstract]   [Full Text] [Related]  

  • 12. [Beta blockers in post-infarction state].
    Schultheiss HP; Tschöpe C
    Herz; 2002 Aug; 27 Suppl 1():26-9. PubMed ID: 12229255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Angiotensin-converting enzyme inhibitors. Principles and rules of their use].
    Juillière Y
    Rev Prat; 2001 Sep; 51(14):1601-7. PubMed ID: 11757278
    [No Abstract]   [Full Text] [Related]  

  • 14. [Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction].
    Kanopskiĭ SG; Staritskiĭ AG; Bozhko AA
    Kardiologiia; 2004; 44(10):13-8. PubMed ID: 15477784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACE inhibitors in heart failure: what more do we need to know?
    Demers C; Mody A; Teo KK; McKelvie RS
    Am J Cardiovasc Drugs; 2005; 5(6):351-9. PubMed ID: 16259523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial.
    McMurray J; Køber L; Robertson M; Dargie H; Colucci W; Lopez-Sendon J; Remme W; Sharpe DN; Ford I
    J Am Coll Cardiol; 2005 Feb; 45(4):525-30. PubMed ID: 15708698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy.
    Kajimoto H; Ishigaki K; Okumura K; Tomimatsu H; Nakazawa M; Saito K; Osawa M; Nakanishi T
    Circ J; 2006 Aug; 70(8):991-4. PubMed ID: 16864930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between mortality and persistent use of beta blockers and angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and coronary artery disease.
    Allen LaPointe NM; Zhou Y; Stafford JA; Hernandez AF; Kramer JM; Anstrom KJ
    Am J Cardiol; 2009 Jun; 103(11):1518-24. PubMed ID: 19463509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).
    Komajda M; Lutiger B; Madeira H; Thygesen K; Bobbio M; Hildebrandt P; Jaarsma W; Riegger G; Rydén L; Scherhag A; Soler-Soler J; Remme WJ;
    Eur J Heart Fail; 2004 Jun; 6(4):467-75. PubMed ID: 15182773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching to once-daily evidence-based [beta]-blockers in patients with systolic heart failure or left ventricular dysfunction after myocardial infarction.
    Albert NM
    Crit Care Nurse; 2007 Dec; 27(6):62-72. PubMed ID: 18032686
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.